These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1621751)

  • 1. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.
    McCarty J; Ruoff GE; Jacobson KD
    Am J Med; 1992 Jun; 92(6A):80S-85S. PubMed ID: 1621751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
    Hyslop DL; Bischoff W
    Am J Med; 1992 Jun; 92(6A):86S-94S. PubMed ID: 1621752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Ruoff GE
    Clin Ther; 1992; 14(1):41-53. PubMed ID: 1576625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loracarbef vs. cefaclor in pediatric skin and skin structure infections.
    Hanfling MJ; Hausinger SA; Squires J
    Pediatr Infect Dis J; 1992 Aug; 11(8 Suppl):S27-30. PubMed ID: 1513609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria.
    Iravani A
    Clin Ther; 1992; 14(1):54-63. PubMed ID: 1576626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loracarbef versus cefaclor in the treatment of urinary tract infections in women.
    Iravani A
    Antimicrob Agents Chemother; 1991 Apr; 35(4):750-2. PubMed ID: 2069382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic therapy for urinary tract infections.
    Iravani A; Bischoff W
    Am J Med; 1992 Jun; 92(6A):95S-100S. PubMed ID: 1621753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in an adult population.
    McCarty J
    Am J Med; 1992 Jun; 92(6A):74S-79S. PubMed ID: 1621750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
    Therasse DG
    Am J Med; 1992 Jun; 92(6A):20S-25S. PubMed ID: 1621742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. The Cefprozil Multicenter Study Group.
    Parish LC; Doyle CA; Durham SJ; Wilber RB
    Clin Ther; 1992; 14(3):458-69. PubMed ID: 1638587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cefaclor AF in the treatment of skin and skin-structure infections.
    Schupbach CW; Olovich KG; Dere WH
    Clin Ther; 1992; 14(3):470-9. PubMed ID: 1638588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
    Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections.
    Montero L
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():125-31. PubMed ID: 8818853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults.
    McCarty J; Hernon Y; Linn L; Therasse DG; Molina A; Bleile N
    Clin Ther; 1992; 14(1):30-40. PubMed ID: 1576624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.
    Müller O; Wettich K
    Infection; 1992; 20(3):176-82. PubMed ID: 1463527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.
    Iravani A; Doyle CA; Durham SJ; Wilber RB
    Clin Ther; 1992; 14(2):314-26. PubMed ID: 1611652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.
    Hyslop DL; Jacobson K; Guerra FJ
    Clin Ther; 1992; 14(2):254-67. PubMed ID: 1611648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
    Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of cefpodoxime proxetil in the treatment of skin and soft tissue infections. A double blind comparison of cefpodoxime proxetil and cefaclor].
    Yura J; Shinagawa N; Mizuno A; Watanabe S; Ando M; Sakai K; Ueda T; Morimoto K; Nakamura T; Hashimoto I
    Jpn J Antibiot; 1988 Oct; 41(10):1517-37. PubMed ID: 3060626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Members of the Ceftibuten Otitis Media International Study Group.
    Blumer JL; Mclinn SE; Deabate CA; Kafetzis DA; Perrotta RJ; Salgado O
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S115-20. PubMed ID: 7567311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.